Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the approximately $125 million public offering of common stock of NeoGenomics, Inc. The common stock is listed on the NASDAQ Global Select Market under the symbol “NEO.”

NeoGenomics specializes in cancer genetics testing and information services. NeoGenomics provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. NeoGenomics’ Pharma Services division serves pharmaceutical clients in clinical trials and drug development. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks and managed care organizations throughout the United States.

The Davis Polk corporate team included partner Sophia Hudson and associates Ferrell Maguire Keel, Leigh Katz and Grecia Barboza. The intellectual property and technology team included partner Frank J. Azzopardi and associates Elizabeth R. Diggs and Christopher C. Woller. Associates Anne E. McGinnis and Yixuan Long provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post